ORTHOCELL LIMITED (OCC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OCC

OCC - ORTHOCELL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.09
Index: ALL-ORDS

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.725

10 Sep
2026

0.000

OPEN

$0.73

0.000

HIGH

$0.73

244,100

LOW

$0.72

TARGET
$1.13 55.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
OCC: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 5.3 - 3.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-5.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.4 M
Book Value Per Share xxxxxxxxxxxxxxx12.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-13.3 M
Net Profit Margin xxxxxxxxxxxxxxx-121.98 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-56.82 %
Return on Invested Capital xxxxxxxxxxxxxxx-55.70 %
Return on Assets xxxxxxxxxxxxxxx-30.91 %
Return on Equity xxxxxxxxxxxxxxx-56.82 %
Return on Total Capital xxxxxxxxxxxxxxx-71.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx44 M
Price To Book Value xxxxxxxxxxxxxxx5.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx11.12 %
Cost of Goods Sold xxxxxxxxxxxxxxx8 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx22 M
Research & Development xxxxxxxxxxxxxxx4 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/09/2026

1

Speculative Buy

$1.13

55.86%

Orthocell's FY26 revenue rose 45% to $11.4m, broadly in line with Bell Potter's forecast.

Underlying sales revenue increased 65% to $8.7m despite a limited contribution from the US launch of Remplir, the analysts observe.

Strong progress expanding US access for Remplir is noted, though revenue has yet to scale with the growing hospital and surgeon footprint.

The broker's focus now shifts to increasing repeat utilisation and converting US market access into revenue. UK and European regulatory clearance is expected by the end of 2026.

Target lowered to $1.13 from $1.19 and the Speculative Buy rating is maintained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.80 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

22/04/2026

1

Speculative Buy

$1.26

73.79%

Canaccord Genuity maintains a Speculative Buy rating and $1.26 price target for Orthocell following the 3Q26 update.

Group revenue of $3.2m for the quarter brought the year-to-date total to $9.4m, representing a 45% increase versus the previous period.

US sales debuted during this quarter with $300,000 in revenue from the Remplir product launch.

The valuation is lowered, primarily due to currency fluctuations as the AUD strengthened against the USD.

Commentary observes normalised cash burn moderated during the period, with the company reporting $48m in cash at the end of the quarter.

FORECAST
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.90 cents.
Access Extra Coverage Research History >

OCC STOCK CHART

FNArena News on OCC

1
FNArena Corporate Results Monitor – 02-09-2026

Sep 02 2026 - Australia
2
Australian Broker Call *Extra* Edition – Apr 22, 2026

Apr 22 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Dec 18, 2025

Dec 18 2025 - Daily Market Reports
4
Next Week At A Glance – 10-24 Oct 2025

Oct 17 2025 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Oct 25, 2024

Oct 25 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps